 TORONTO, ON ACCESSWIRE November 5, 2019 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. Edesa completed a reverse acquisition with a Nasdaq listed company in June of this year and has since initiated a Phase 2b clinical study of its lead product candidate in allergic contact dermatitis. 